is tafamidis available in australia?
It has been approved in many countries, including Brazil, Israel, South Korea, those in the European Union, and in the United States. In some other countries, e.g. Australia, it has orphan designation* for the treatment of transthyretin cardiomyopathy (TTR-CM)–in which the disease affects the heart muscle.